Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies to treat autoimmune and inflammatory diseases.
Sonoma Biotherapeutics has raised $300K in total funding. The most recent round was Grant. The last funding was announced in November 2025.
Sonoma Biotherapeutics's investors include ARCH Venture Partners, 8VC, Janus Henderson Investors, Frazier Healthcare Partners, Lilly Asia Ventures.
Sonoma Biotherapeutics is headquartered in South San Francisco, United States.
Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies to treat autoimmune and inflammatory diseases.
Sonoma Biotherapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sonoma Biotherapeutics — Funding & Investors." VCBacked, November 3, 2025, https://www.vcbacked.co/company/sonoma-biotherapeutics. Accessed July 19, 2026.
VCBacked. (2025). Sonoma Biotherapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/sonoma-biotherapeutics
{{cite web |title=Sonoma Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sonoma-biotherapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated